The strategy and clinical relevance of in vitro models of MAP resistance in osteosarcoma: a systematic review

Over the last 40 years osteosarcoma (OS) survival has stagnated with patients commonly resistant to neoadjuvant MAP chemotherapy involving high dose methotrexate, adriamycin (doxorubicin) and platinum (cisplatin). Due to the rarity of OS, the generation of relevant cell models as tools for drug disc...

Descripción completa

Detalles Bibliográficos
Autores principales: Tippett, Victoria L., Tattersall, Luke, Ab Latif, Norain B., Shah, Karan M., Lawson, Michelle A., Gartland, Alison
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859755/
https://www.ncbi.nlm.nih.gov/pubmed/36434179
http://dx.doi.org/10.1038/s41388-022-02529-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9859755/
https://www.ncbi.nlm.nih.gov/pubmed/36434179
http://dx.doi.org/10.1038/s41388-022-02529-x

Ejemplares similares